Christophe Weber - Takeda Pharmaceutical CEO Pres

All Insiders . Germany . 
Stock . Takeda Pharmaceutical . Stakeholders . Insider . Christophe Weber
TKD Stock  EUR 25.52  0.22  0.87%   

Insider

Christophe Weber is CEO Pres of Takeda Pharmaceutical
Age 57
Phone81 3 3278 2111
Webhttps://www.takeda.com

Takeda Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Takeda Pharmaceutical has accumulated 4.14 T in total debt with debt to equity ratio (D/E) of 114.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Takeda Pharmaceutical has a current ratio of 1.2, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Takeda Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Takeda Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Takeda Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Takeda to invest in growth at high rates of return. When we think about Takeda Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Steven FrankZoetis Inc
N/A
Akira KatoShionogi Co
N/A
Susumu MitsumoriShionogi Co
N/A
John KellerShionogi Co
58
Gary HendlerEisai Co
57
Haruo NaitoEisai Co
76
MD FAANEisai Co
73
Tatsuyuki YasunoEisai Co
55
Nadeem SarwarEisai Co
N/A
Sayoko SasakiEisai Co
55
Teruyuki MasakaEisai Co
45
Wetteny JosephZoetis Inc
51
Yosuke AkitaEisai Co
58
William PriceZoetis Inc
N/A
Robert PolzerZoetis Inc
54
Wafaa MamilliZoetis Inc
56
Yanhui FengEisai Co
51
Kohji HanasakiShionogi Co
N/A
Ryuichi KiyamaShionogi Co
N/A
Takeshi ShiotaShionogi Co
N/A
Kazuhiro HatanakaShionogi Co
N/A
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 49578 people. Takeda Pharmaceutical (TKD) is traded on Frankfurt Exchange in Germany and employs 47,347 people.

Management Performance

Return On Equity0.0477
Return On Asset0.0247

Takeda Pharmaceutical Leadership Team

Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christophe Weber, CEO Pres
Christopher OReilly, Global Fin
Andrew Plump, Pres Director
Seigo Izumo, Chair Board
Gabriele Ricci, Chief Officer
Salvatore Alesci, Member Policy
Iwaaki Taniguchi, Sr Department
Constantine Saroukos, CFO Director
Haruhiko Hirate, Member Board
Norimasa Takeda, Chief Controller

Takeda Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0477
Return On Asset0.0247
Profit Margin0.07 %
Operating Margin0.13 %
Current Valuation71.16 B
Shares Outstanding1.56 B
Shares Owned By Insiders1.20 %
Shares Owned By Institutions41.30 %
Price To Earning19.43 X
Price To Book0.95 X

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in Takeda Stock

Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY